Superworth

Verastem revenue VSTM

Sales by quarter and over the last twelve months, from 2018.

Last 12 months, to Jun 30, 2026
$87.5M
Latest quarter, Q2 FY26
$40.1M
+1775% on a year earlier
Fiscal year 2025
n/a

Verastem's revenue was $87.5M over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was $40.1M, up 1775% on the same quarter a year before.

Over the five fiscal years to FY2025 it shrank 100% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025n/an/a
FY2024n/an/a
FY2022$2.6M+26%
FY2021$2.1M−98%
FY2020$88.5M+407%
FY2019$17.5Mn/a
FY2018n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$40.1M+1775%$87.5M
Q1 FY26$18.7Mn/a$49.6M
Q4 FY25$17.5Mn/an/a
Q3 FY25$11.2Mn/an/a
Q2 FY25$2.1M−79%n/a
Q4 FY24$0n/an/a
Q3 FY24$0n/an/a
Q2 FY24$10Mn/an/a
Q4 FY22$0−100%$2.6M
Q3 FY22$0−100%$3.1M
Q2 FY22$0−100%$3.1M
Q1 FY22$2.6M+158%$3.6M

Against its peers

Companies in Drug Manufacturers - General nearest Verastem's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
VSTMVerastem$87.5M
ABUSArbutus Biopharma$181.7M
AMPHAmphastar Pharmaceuticals$730M+1% a year
COLLCollegium Pharmaceutical$808.2M+14% a year
OMEROmerosn/m
CRMDCorMedix$462.2M+281% a year
ZVRAZevra Therapeutics$136.1M+119% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
PCRXPacira BioSciences$746.2M+6% a year
PBYIPuma Biotechnology$231.2M−3% a year
ANABAnaptysbion/m
Peer median$425.8M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Verastem

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.